Prolongation of chemotherapeutically induced remission of a syneneic murine leukemia by L-2,3,5,6-tetrahydro-6-phenylimidazo[2.1-BETA]thiazole hydrochloride.
L-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-beta]thiazole hydrochloride (LMS), when used in concert with 1,3-bis(2-chloroethyl)-1-nitrosourea, resulted in a significantly higher percentage of long-term leukemic-free survivors. The additive effect provided by LMS treatment was evident during the immunosuppressed period induced by 1,3-bis(2-chloroethyl)-1-nitrosourea treatment and when tumor load was minimal. Treatment with LMS alone did not appear to possess any significant antitumor effect. The beneficial effect of LMS treatment may be attributable to the immunostimulatory activity reported for this drug. LMS appears to possess characteristics that make it an excellent candidate for use as an immunostimulant in cancer combined modality treatment.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002330:Carmustine / Q000494:pharmacology / Q000627:therapeutic use*; D006084:Graft Rejection / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000276:immunology; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D008979:Moloney murine leukemia virus; D009368:Neoplasm Transplantation; D012075:Remission, Spontaneous
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D007978:Levamisole; D002330:Carmustine